Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Peer Reviewed
See detailPrevention of metabolic alterations by insulin supplements administered either before or after 2-h nocturnal interruption of CSII.
Scheen, André ULg; Henrivaux, P.; Jandrain, Bernard ULg et al

in Diabetes Care (1987), 10(5), 567-72

To evaluate the efficacy of a bolus insulin injection to prevent the metabolic alterations induced by a 2-h nocturnal interruption of a continuous subcutaneous insulin infusion (CSII), nine type I ... [more ▼]

To evaluate the efficacy of a bolus insulin injection to prevent the metabolic alterations induced by a 2-h nocturnal interruption of a continuous subcutaneous insulin infusion (CSII), nine type I (insulin-dependent) C-peptide-negative diabetic patients were studied from 2200 to 0800 h during two randomized tests. An insulin bolus (2.1 +/- 0.2 U) was administered via the pump either at 2300 h, just before CSII interruption, or at 0100 h, after reactivating the pump at its usual basal rate (1.05 +/- 0.11 U/h). The insulin bolus at 2300 h induced a significant rise in plasma free-insulin levels at 2400 h (+6.9 +/- 1.8 mU/L, P less than .01), resulting in an early and marked fall in blood glucose concentrations between 2300 and 0100 h (-2.7 +/- 0.5 mM, P less than .001), with hypoglycemic values in five patients. The insulin bolus at 0100 h counteracted the fall in plasma free-insulin levels observed between 2300 and 0100 h and significantly increased plasma insulin at 0200 h (+3.2 +/- 0.8 mU/L, P less than .01). Blood glucose concentrations that remained stable during the 2-h arrest of the pump fell significantly between 0100 and 0400 h (-2.1 +/- 0.5 mM, P less than .005). This fall rate was significantly lower than that measured within the 3 h after the insulin bolus given before CSII interruption but significantly higher than that observed in a reference control group of patients whose pump was functioning normally throughout the night.(ABSTRACT TRUNCATED AT 250 WORDS) [less ▲]

Detailed reference viewed: 8 (0 ULg)
Peer Reviewed
See detailPrevention of Murine Radiogenic Thymic Lymphomas by Tumor Necrosis Factor or by Marrow Grafting
Humblet, Chantal ULg; Greimers, Roland ULg; Delvenne, Philippe ULg et al

in Journal of the National Cancer Institute (1996), 88(12), 824-31

BACKGROUND: Split-dose irradiation (1.75 Gy given weekly for 4 weeks) of C57BL/Ka mice induces the emergence of preleukemic cells (PLCs). These cells develop into leukemic cells after a latency period of ... [more ▼]

BACKGROUND: Split-dose irradiation (1.75 Gy given weekly for 4 weeks) of C57BL/Ka mice induces the emergence of preleukemic cells (PLCs). These cells develop into leukemic cells after a latency period of 3-6 months. The survival and transformation of PLCs are dependent on radiation-induced alterations of the thymic epithelium and of resident lymphocyte (i.e., thymocyte) subpopulations in the thymus. PLCs can be eliminated, concomitantly with the restoration of the thymus, by grafting bone marrow cells immediately after the last irradiation. Our hypothesis was that any agent able to restore the thymus after leukemogenic irradiation would exert the same effects as a bone marrow graft. Tumor necrosis factor-alpha (TNF-alpha) is one such possible agent, since it has been shown to modulate some functions of the thymic epithelium and thymocyte subpopulations. PURPOSE: The goal of this study was to assess the ability of repeated intraperitoneal injections of TNF-alpha to functionally replace bone marrow transplantation in the restoration of normal intrathymic lymphopoiesis and in the prevention of thymic lymphomas in split-dose-irradiated mice. METHODS: We replaced the bone marrow graft with repeated injections of TNF-alpha (25 000 U/injection) in the split-dose-irradiated (4 x 1.75 Gy) C57BL/Ka mouse model. We analyzed the expression of the cell differentiation markers CD4 and CD8 on thymocytes by flow cytometry. We also studied the thymic environment by isolating thymic nurse cells, the bone marrow prothymocyte activity by analyzing thymic repopulation, and the evolution of PLCs by an in vivo transplantation assay. Local production of TNF-alpha after bone marrow grafting was examined by in situ hybridization. Injections of anti-TNF-alpha antibodies were given to split-dose-irradiated mice to test the effect of neutralizing TNF-alpha in vivo. One-way analysis of variance and Newman-Keuls two-tailed tests were used to test statistical significance. RESULTS: Multiple injections of TNF-alpha into split-dose-irradiated mice did not influence bone marrow prothymocyte activity but restored thymocyte subpopulations and thymic epithelium, induced the disappearance of PLCs, and prevented the development of lymphomas. Moreover, a bone marrow graft significantly stimulated intrathymic production of TNF-alpha messenger RNA (P<.01), and anti-TNF-alpha antibodies partially inhibited the antilymphomatous effects of bone marrow graft in split-dose-irradiated mice (P<.05). CONCLUSION: These data strongly suggest that TNF-alpha is a mediator that is involved in the mechanisms by which bone marrow transplantation functions to prevent thymic lymphomas in split-dose-irradiated mice. IMPLICATIONS: Cytokines might be used in some biological systems, particularly in the hemopoietic system, as a therapeutic agent for the secondary prevention of cancer. [less ▲]

Detailed reference viewed: 11 (2 ULg)
Peer Reviewed
See detailPrevention of neonatal group B streptococcal disease in Belgium: hospital policy, obstetricians' practice and laboratory processing
MELIN, Pierrette ULg; Schmitz, Myriam; Heinrichs, I. et al

Poster (2000, November 25)

Detailed reference viewed: 7 (0 ULg)
Peer Reviewed
See detailPrevention of neonatal group B streptococcal disease in Belgium: hospital policy, obstetricians' practice and laboratory processing
MELIN, Pierrette ULg; Schmitz, Myriam; Heinrichs, I. et al

in American Society of Microbiology (Ed.) Program and Abstracts of the 40th Intersciences Conference on Antimicrobial Agents and Chemotherapy (2000, September)

Detailed reference viewed: 20 (5 ULg)
Full Text
Peer Reviewed
See detailPrevention of Osteoporosis with Nasal Salmon Calcitonin: Effect of Anti-Salmon Calcitonin Antibody Formation
Reginster, Jean-Yves ULg; Gaspar, S; Deroisy, Rita ULg et al

in Osteoporosis International : A Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis & the National Osteoporosis Foundation of the USA (1993), 3

The amino acid sequence of salmon calcitonin (SCT) differs considerably from that of the human hormone and specific antibodies (Ab) develop in a significant proportion of patients after parenteral or ... [more ▼]

The amino acid sequence of salmon calcitonin (SCT) differs considerably from that of the human hormone and specific antibodies (Ab) develop in a significant proportion of patients after parenteral or nasal administration of SCT. Controversy remains regarding the functional importance of these Ab. We report on the development of specific anti-SCT Ab in a population of postmenopausal women receiving nasal SCT for prevention of postmenopausal bone loss, and compare the effects of nasal SCT in women with or without Ab. Thirty-nine per cent of women developed Ab after 6 months of treatment with SCT, 52% after 12 months, and 61% after 18 and 24 months. After 24 months the AB titre was 3.47-17.7 x 10(-9) M/l (mean +/- SD: 13.3 +/- 3.1 x 10(-9) M/l). No significant differences appeared between the changes in lumbar bone mineral density (BMD) measured in the whole population (n = 44) (mean +/- SD: +1.06 +/- 3.9%), the patients without Ab (n = 17) (+0.05 +/- 3.7%) or in those with Ab (n = 27) (+1.7 +/- 4.6%). During the same period, a control population randomly assigned to a 500 mg/day calcium intake showed a significant loss of lumbar BMD (-4.57 +/- 4.9%) (p < 0.01). In conclusion, in healthy postmenopausal women nasal SCT seems to maintain the same preventive effect against bone loss whether or not Ab are present. [less ▲]

Detailed reference viewed: 11 (3 ULg)
See detailPrevention of perinatal GBS Diseases: Recommendations in European Countries, Proposal for Belgium
MELIN, Pierrette ULg

Scientific conference (2001, November 17)

Detailed reference viewed: 9 (0 ULg)
See detailPrevention of perinatal GBS infections: update and guidelines
MELIN, Pierrette ULg

Conference (2004, December 17)

Detailed reference viewed: 13 (0 ULg)
Full Text
See detailPrevention of perinatal group B streptococcak diseases: update and guidelines
MELIN, Pierrette ULg

in Ducoffre, Geneviève (Ed.) Program and Abstracts book of 2005 Symposium of ISP (2005, November 17)

Face à l’importance et à la gravité des infections périnatales à streptocoques du groupe B (GBS), depuis dix ans, différentes approches préventives ont été proposées. Le point commun est l’administration ... [more ▼]

Face à l’importance et à la gravité des infections périnatales à streptocoques du groupe B (GBS), depuis dix ans, différentes approches préventives ont été proposées. Le point commun est l’administration intraveineuse d’antibiotiques pendant le travail et l’accouchement aux patientes identifiées « à risque » soit par un dépistage de colonisation maternelle pendant la grossesse, soit par la présence de facteurs de risque définis. En 2002, après quelques années d’implémentation et d’adoption des recommandations éditées par le CDC (Centers for Diseases Control and Prevention, Atlanta, USA) en 1996, différentes études ont évalué l’efficacité des alternatives et ont démontré pour différentes raisons, la supériorité du dépistage pendant la grossesse pour l’identification des mères « à risque ». C’est pourquoi, en août 2002, le CDC publiait une version révisée des recommandations en proposant un dépistage universel, c'est-àdire de TOUTES les femmes enceintes. Parallèlement d’autres pays, notamment la France et la Belgique, évaluaient aussi l’efficacité et la faisabilité de différentes stratégies plus ou moins proches de celles du CDC. Depuis juillet 2003, les recommandations belges « Prevention of Perinatal Group B streptococcal Infections. Guidelines from the Belgium Health Council . (SHC. 721) » sont disponibles sur le site du CSH : (http://www.health.fgov.be/CSH_HGR/Francais/Brochures/GBS_2003.pdf et http://www.health.fgov.be/CSH_HGR/Nederlands/Brochures/GBS_2003.pdf). Ces recommandations sont très proches de celles du CDC moyennant quelques adaptations techniques et de prises en charge des nouveau-nés et, qui devraient en améliorer l’efficacité. Ces recommandations belges seront présentées et discutées. L’efficacité optimale attendue de ces recommandations est une réduction de 75% des cas d’infection néonatale précoce confirmés par culture. Pour atteindre cet objectif, la communication et une coordination multidisciplinaires sont indispensables entre le service de gynécologie-obstétrique, le laboratoire, le bloc d’accouchement et le service de néonatologie. [less ▲]

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailPrevention of Perinatal Group B Streptococcal Diseases: Belgian Guidelines
Melin, Pierrette ULg

in Round Table Series (2007), 85

Detailed reference viewed: 26 (3 ULg)
Full Text
See detailPrevention of Perinatal Group B Streptococcal Infections - Guidelines from the Belgian Health Council, 2003 (SHC.7721)
Working party of experts, Superior Health Concil; Dubois, J. J.; MELIN, Pierrette ULg et al

Book published by Superior Health Council (2003)

Detailed reference viewed: 16 (2 ULg)
Full Text
Peer Reviewed
See detailPrevention of postmenopausal bone loss by administration of boron
Biquet, I; COLLETTE, Julien ULg; Dauphin, JF et al

in Osteoporosis International (1996), 6(S1), 249

Detailed reference viewed: 7 (2 ULg)
Full Text
Peer Reviewed
See detailPrevention of Postmenopausal Bone Loss by Rectal Calcitonin
Reginster, Jean-Yves ULg; Jupsin, Isabelle ULg; Deroisy, Rita ULg et al

in Calcified Tissue International (1995), 56

A group (150) of healthy women, who had been menopausal for less than 5 years and who had never received any form of treatment to prevent bone loss were entered into a randomized, controlled study ... [more ▼]

A group (150) of healthy women, who had been menopausal for less than 5 years and who had never received any form of treatment to prevent bone loss were entered into a randomized, controlled study comprising three arms. They were randomly allocated to the double-blind administration of five suppositories per week containing either 100 IU of salmon calcitonin or a placebo, or to a group receiving a suppository containing 200 IU of salmon calcitonin three times per week. All women received 500 mg/day of calcium supplementation. After 12 months, bone mineral density (BMD) of the spine, measured by dual energy X-ray absorptiometry, decreased significantly (P < 0.01) in the placebo group by 3.1% (SD: 3.6%) but did not change in the two calcitonin groups [+1.3% (3.5%) with 100 IU/day and +2.3% (4.0%) with 200 IU 3/week]. The differences in response between the placebo group and the two calcitonin groups were significant (P < 0.05), but the difference between the two regimens of calcitonin administration was not. No differences appeared among the three groups for the response at the level of the hip. Evolution of biochemical markers reflecting bone turnover did not differ significantly among groups. Nearly 40% of the women withdrew prematurely because of local (rectal or intestinal) intolerance to repetitive suppositories, with a nonsignificantly different frequency in the placebo or calcitonin groups. We conclude that rectal calcitonin might be an interesting preventive approach against trabecular postmenopausal bone loss but that long-term acceptability of suppositories should be evaluated in view of each patient's sensibility or cultural background. [less ▲]

Detailed reference viewed: 6 (2 ULg)
Peer Reviewed
See detailPrevention of postmenopausal bone loss by tiludronate
Reginster, Jean-Yves ULg; Lecart, MP; DEROISY, Rita ULg et al

in Menopause Digest (1990), 4

Detailed reference viewed: 13 (2 ULg)
Peer Reviewed
See detailPrevention of postmenopausal bone loss by tiludronate
Reginster, Jean-Yves ULg; DEROISY, Rita ULg; Lecart, MP et al

in Japanese Journal of Bone and Metabolism (1990), 8

Detailed reference viewed: 10 (3 ULg)
Full Text
Peer Reviewed
See detailPrevention of Postmenopausal Bone Loss by Tiludronate
Reginster, Jean-Yves ULg; Lecart, M. P.; Deroisy, Rita ULg et al

in Lancet (1989), 2(8678-8679, Dec 23-30), 1469-71

76 healthy women, who had been menopausal for less than 96 months and who had never received any form of treatment to prevent bone loss, were entered into a randomised double-blind study. For the first 6 ... [more ▼]

76 healthy women, who had been menopausal for less than 96 months and who had never received any form of treatment to prevent bone loss, were entered into a randomised double-blind study. For the first 6 months, half the patients received tiludronate 100 mg daily, while the others received placebo. During the second 6 months, all patients received placebo. Bone mineral density of the lumbar spine decreased significantly by 2.1% (SE 0.8%) in the placebo group and did not significantly change in the tiludronate group (+1.33 [0.8]%). The difference in response between the groups was significant, as were the differences between values for corrected urinary hydroxyproline and calcium. Treatment with tiludronate was not followed by increased secretion of parathyroid hormone. A 6 month course of oral tiludronate may counteract postmenopausal bone loss for at least a year by decreasing bone resorption. [less ▲]

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailPrevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities
Reginster, Jean-Yves ULg

in Journal of Internal Medicine (2004), 255(6), 615-628

Postmenopausal osteoporosis (PMO) is a common disease that will become more prevalent in the future, with costly implications for public health. Prevention of the disease and its consequences, namely ... [more ▼]

Postmenopausal osteoporosis (PMO) is a common disease that will become more prevalent in the future, with costly implications for public health. Prevention of the disease and its consequences, namely fractures, is therefore, important for both the individual and society. This review discusses: the goals of PMO prevention; the identification of women at risk, including the use of bone mineral density and bone turnover markers; the relevance in the prevention setting of various current guidelines for PMO management; recent data on therapeutic options for the treatment and prevention of PMO, in particular bisphosphonates, hormone replacement therapy and several other new pharmacological agents. It concludes that it is crucial for PMO prevention to start before disease onset and that, in the light of recent evidence, the existing guidelines need updating if they are to continue to be relevant. [less ▲]

Detailed reference viewed: 16 (0 ULg)
See detailPrevention of Reflective Cracking in Pavements (Chapter 4)
Courard, Luc ULg; Vanelstraete, A.; de Bondt, A. et al

in • Characterization of overlay systems (1997)

Detailed reference viewed: 24 (3 ULg)
Full Text
See detailPrevention of spectators’ violence and safety in football stadiums
Comeron, Manuel ULg

Scientific conference (2007, May 30)

Detailed reference viewed: 39 (9 ULg)